# Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

> **NCT07591831** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer
- Fallopian Tube Cancers
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer

## Interventions

- **DRUG:** Liposomal Irinotecan

## Key facts

- **NCT ID:** NCT07591831
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2027-05-30
- **Final completion:** 2030-05-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07591831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07591831, "Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07591831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*